Dragon Age: The Veilguard Free Trial For EA Play Members Is Out Now

2 weeks ago 3

GameSpot may receive revenue from affiliate and advertising partnerships for sharing this content and from purchases through links.

BioWare has released a free timed trial for Dragon Age: The Veilguard, allowing anyone with an EA Play subscription to check out the game for a limited time at no extra cost. EA Play is included with Game Pass Ultimate, so subscribers to that service get this, too.

The timed trial lets you play the full game, but only for a period of five hours. Time spent in the in-game character creator counts toward the five hours, but you can use the standalone character creator tool to create a hero outside of the game and then import them from the same device/console.

EA Play by itself costs $6/month or $40/year. EA Play Pro, meanwhile, costs $17/month or $120/year. EA Play Pro members get all manner of extras for The Veilguard, including cosmetics and armor sets.

After the five hours is up, players can purchase The Veilguard outright to keep playing. Currently, the game is marked down to $50 on Amazon--you can use the link below to learn more.

The Good and The Bad of Dragon Age: The Veilguard

Want us to remember this setting for all your devices?

Sign up or Sign in now!

Please use a html5 video capable browser to watch videos.

This video has an invalid file format.

Sorry, but you can't access this content!

The Veilguard launched on October 31 from developer BioWare. The studio is not releasing any expansion content, as team members shift to the next Mass Effect. However, BioWare is planning another update for early 2025, though it's unknown what this patch might include.

It was about a decade between Dragon Age: Inquisition and The Veilguard, and due in part to this extensive gap, BioWare admitted that The Veilguard was never going to live up to the hype. GameSpot's Dragon Age: The Veilguard review scored the game an 8/10.

Got a news tip or want to contact us directly? Email [email protected]

Read Entire Article